VYNE - VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202 a Novel BD2-Selective BET Inhibitor | Benzinga
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced GB Patent No. 2621505 entitled "Pyrrolopyridone derivatives useful in the treatment of inflammatory disorders, immune disorders and cancer" has been granted by the United Kingdom's Intellectual Property Office. This granted patent covers the compound in VYNE's VYN202 program and has a 20-year term that will expire in June 2042.
"The granting of this composition of matter patent is key to the development of VYN202, which we believe is the most potent and BD2-selective BET inhibitor in development," said David Domzalski, President and Chief Executive Officer of VYNE. "Obtaining intellectual property protection is an important value driver for VYNE and we will continue to seek protection in additional jurisdictions as we progress our BET inhibitor pipeline."
This newly issued patent is derived from Tay Therapeutics Limited's Patent Cooperation Treaty (PCT) application No. WO 2023/275542 A1, which was filed nationally in multiple jurisdictions, and is exclusively licensed to VYNE. This patent is the first of the national filed applications to be granted.
About VYN202
VYN202 is an innovative, oral small molecule BET inhibitor that has potential class-leading selectivity and potency (BD2 vs. BD1). By maximizing BD2 selectivity, VYNE believes VYN202 has the potential to be a more conveniently administered non-biologic treatment option for both acute control and chronic management of immuno-inflammatory indications, in which the damaging effects of ...